Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N6TD
|
|||
| Former ID |
DNCL002532
|
|||
| Drug Name |
BIW-8962
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1/2 | [1] | |
| Company |
Kyowa Hakko Kirin Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ganglioside GM2 activator (GM2A) | Target Info | . | [2], [3] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01898156) Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci. 2011 Dec;102(12):2157-63. | |||
| REF 3 | National Cancer Institute Drug Dictionary (drug id 618862). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.